bacterial metabolite

ChEBI CHEBI:76969
Associated conditions

Datasets

Paper Phenotype Condition Medium Collection Tested mutants Data Details
Chan TF~Zheng XF, 2000 growth (streaks on agar) sirolimus [25 nM] YPD hap a ~2,216 Discrete
Alamgir M~Golshani A, 2010 growth (colony size) streptomycin [40 mg/ml] hap a 4,669 Quantitative
Alamgir M~Golshani A, 2010 growth (colony size) cycloheximide [45 ng/ml] hap a 4,669 Quantitative
Xie MW~Huang J, 2005 growth (colony size) sirolimus [10 nM] hap a/het 5,784 Quantitative
Xie MW~Huang J, 2005 growth (colony size) sirolimus [30 nM] hap a/het 5,784 Quantitative
Kwak YS~Weller DM, 2011 growth (spot assay) 2,4-diacetylphloroglucinol [200 ug/ml] hap a 4,945 Discrete
Blackburn AS~Avery SV, 2003 growth (MIC) oxytetracycline [256 ug/ml] hap a ~4,800 Discrete
Blackburn AS~Avery SV, 2003 growth (MIC) vancomycin [256 ug/ml] hap a ~4,800 Discrete
Parsons AB~Boone C, 2004 growth (colony size) sirolimus [0.015 ug/ml] hap a ~4,700 Discrete
Parsons AB~Boone C, 2004 growth (colony size) cycloheximide [0.1 ug/ml] hap a ~4,700 Discrete
Kwak YS~Weller DM, 2011 growth (culture turbidity) 2,4-diacetylphloroglucinol [40 ug/ml] hap a 4,945 Quantitative
Neklesa TK~Davis RW, 2008 growth (relative abundance in pooled culture) sirolimus [7.5 ng/ml] hom ~4,757 Discrete
Parsons AB~Boone C, 2006 growth (relative abundance in pooled culture) amphotericin B [0.76 uM] hap a 4,111 Quantitative
Parsons AB~Boone C, 2006 growth (relative abundance in pooled culture) nigericin [69 uM] hap a 4,111 Quantitative
Parsons AB~Boone C, 2006 growth (relative abundance in pooled culture) oligomycin [127 uM] hap a 4,111 Quantitative
Parsons AB~Boone C, 2006 growth (relative abundance in pooled culture) sirolimus [5.5 pM] hap a 4,111 Quantitative
Parsons AB~Boone C, 2006 growth (relative abundance in pooled culture) trichostatin A [99.2 uM] hap a 4,111 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) aclacinomycin A [32.25 uM], time [o/n + 20 gen] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.31 uM], time [o/n + 20 gen] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) cycloheximide [32.3 uM], time [o/n + 20 gen] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) sirolimus [4.88 nM], time [o/n + 20 gen] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) sirolimus [5 nM], time [o/n + 20 gen] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) sirolimus [6 nM], time [o/n + 20 gen] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) sirolimus [9 nM], time [5 gen] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) sirolimus [9 nM], time [o/n + 10 gen] hom 4,742 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) sirolimus [9 nM], time [o/n + 5 gen] hom 4,742 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) bafilomycin A1 [43.69 uM] YPD hom 4,511 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) trichostatin A [200 uM] YPD hom 4,501 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ascomycin [100 uM] YPD hom 4,518 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ravidomycin [12.745 uM] YPD hom 4,516 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) boromycin [4 uM] YPD hom 4,508 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) sirolimus [1 nM] YPD hom 4,516 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) aclacinomycin A [4.857 uM] YPD hom 4,511 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [12 uM] YPD hom 4,489 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) cycloheximide [0.03 uM] YPD hom 4,544 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) soraphen A [0.5 uM] YPD hom 4,489 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) chondramide [90 uM] YPD hom 4,507 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) hygrolidin [7.5 uM] YPD hom 4,496 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) borrelidin [45 uM] YPD hom 4,543 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [8 uM] YPD hom 4,511 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) elaiophylin [30 uM] YPD hom 4,520 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) phleomycin D1 [0.01 uM] YPD hom 4,539 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ravidomycin [10 uM] YPD hom 4,506 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) sirolimus [0.2 nM] YPD hom 4,516 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) sirolimus [0.5 nM] YPD hom 4,516 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) sirolimus [0.8 nM] YPD hom 4,516 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) cycloheximide [0.05 uM] YPD hom 4,544 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) chondramide [110 uM] YPD hom 4,525 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [15 uM] YPD hom 4,503 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) phleomycin D1 [0.012 uM] YPD hom 4,514 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) phleomycin D1 [0.05 uM] YPD hom 4,542 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) phleomycin D1 [0.1 uM] YPD hom 4,539 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) phleomycin D1 [0.3 uM] YPD hom 4,539 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) tacrolimus (anhydrous) [29.80 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) sirolimus [4.00 nM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) amphotericin B [148.00 nM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) sirolimus [2.00 nM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) sirolimus [362.00 pM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) cycloheximide [667.00 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) (+)-caryolan-1-ol [24.72 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunorubicin [18.50 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunorubicin [22.37 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) amphotericin B [100.00 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) sirolimus [1.00 nM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) tacrolimus (anhydrous) [100.00 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) aclacinomycin A [5.55 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunorubicin [9.88 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) nigericin [15.30 uM] hom 4,810 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) ikarugamycin [104.00 uM] hom 4,810 Quantitative
Lum PY~Shoemaker DD, 2004 growth (relative abundance in pooled culture) amphotericin B [600 ng/ml] SC het 3,503 Quantitative only for hits
Lum PY~Shoemaker DD, 2004 growth (relative abundance in pooled culture) cycloheximide [10 ng/ml] SC het 3,503 Quantitative only for hits
Lum PY~Shoemaker DD, 2004 growth (relative abundance in pooled culture) daunorubicin [40 ng/ml] SC het 3,503 Quantitative only for hits
Dudley AM~Church GM, 2005 growth (spot assay) cycloheximide [0.18 ug/ml] YPD hom 4,621 Discrete
Dudley AM~Church GM, 2005 growth (spot assay) sirolimus [0.1 ug/ml] YPD hom 4,621 Discrete
Neklesa TK~Davis RW, 2009 TORC1 activity (Dal80pr-GFP) sirolimus [20 ng/ml] hom ~5,100 None
Jakubkova M~Tomaska L, 2016 growth (spot assay) nigericin [0.15-0.5 mg/l] sSG hap a 4,993 Discrete
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) bafilomycin A1 [43.69 uM] YPD het 5,801 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ascomycin [100 uM] YPD het 5,801 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ravidomycin [12.745 uM] YPD het 5,782 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) boromycin [4 uM] YPD het 5,770 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) aclacinomycin A [4.857 uM] YPD het 5,801 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [12 uM] YPD het 5,790 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) cycloheximide [0.03 uM] YPD het 5,810 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) soraphen A [0.5 uM] YPD het 5,790 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) chondramide [90 uM] YPD het 5,768 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) hygrolidin [7.5 uM] YPD het 5,770 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) borrelidin [45 uM] YPD het 5,780 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [8 uM] YPD het 5,794 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) elaiophylin [30 uM] YPD het 5,801 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) phleomycin D1 [0.01 uM] YPD het 5,786 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) ravidomycin [10 uM] YPD het 5,786 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) sirolimus [0.2 nM] YPD het 5,782 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) sirolimus [0.5 nM] YPD het 5,782 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) sirolimus [0.8 nM] YPD het 5,782 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) cycloheximide [0.05 uM] YPD het 5,810 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) nigericin [15 uM] YPD het 5,779 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) phleomycin D1 [0.012 uM] YPD het 5,802 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) phleomycin D1 [0.05 uM] YPD het 5,804 Quantitative
Hoepfner D~Movva NR, 2014 growth (relative abundance in pooled culture) phleomycin D1 [0.1 uM] YPD het 5,786 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.31 uM], time [o/n + 20 gen] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) sirolimus [4.88 nM], time [o/n + 20 gen] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) sirolimus [5 nM], time [o/n + 20 gen] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) sirolimus [6 nM], time [o/n + 20 gen] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [40 uM], flucytosine [15.6 uM], time [o/n + 20 gen] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [20 uM], flucytosine [15.6 uM], time [o/n + 20 gen] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) aclacinomycin A [15.63 uM], time [o/n + 20 gen] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.62 uM], time [o/n + 20 gen] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.31 uM], flucytosine [15.6 uM], time [o/n + 20 gen] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.62 uM], flucytosine [15.6 uM], time [o/n + 20 gen] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [10 uM], time [o/n + 20 gen] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) borrelidin [15.63 uM], time [o/n + 20 gen] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) cycloheximide [0.03 nM], time [o/n + 20 gen] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) cycloheximide [100 uM], time [o/n + 20 gen] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) daunorubicin [125 uM], time [o/n + 20 gen] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) daunorubicin [250 uM], time [o/n + 15 gen] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) filipin III [100 uM], time [o/n + 20 gen] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.31 uM], fluconazole [31.25 uM], time [o/n + 20 gen] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [20 uM], fluconazole [65.3 uM], time [o/n + 20 gen] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [40 uM], fluconazole [65.3 uM], time [o/n + 20 gen] het 5,720 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.31 uM], itraconazole [8.8 uM], time [o/n + 20 gen] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) amphotericin B [0.62 uM], itraconazole [8.8 uM], time [o/n + 20 gen] het 5,701 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) sirolimus [9 nM], time [o/n + 20 gen] het 5,686 Quantitative
Hillenmeyer ME~Giaever G, 2008 growth (relative abundance in pooled culture) trichostatin A [3.91 uM], time [o/n + 20 gen] het 5,686 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) tacrolimus (anhydrous) [29.80 uM] het 931 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) amphotericin B [148.00 nM] het 880 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) sirolimus [362.00 pM] het 855 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) cycloheximide [667.00 uM] het 1,052 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) (+)-caryolan-1-ol [24.72 uM] het 839 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunorubicin [22.37 uM] het 818 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) sirolimus [1.00 nM] het 818 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunorubicin [9.88 uM] het 815 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) nigericin [15.30 uM] het 993 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) sirolimus [4.00 nM] het 881 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) sirolimus [2.00 nM] het 880 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) daunorubicin [18.50 uM] het 1,052 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) amphotericin B [100.00 uM] het 818 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) tacrolimus (anhydrous) [100.00 uM] het 818 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) aclacinomycin A [5.55 uM] het 815 Quantitative
Lee AY~Giaever G, 2014 growth (relative abundance in pooled culture) ikarugamycin [104.00 uM] het 993 Quantitative
Krol K~Skoneczna A, 2015 growth (relative abundance in pooled culture) phleomycin D1 [5-15 ug/ml] hom ~5,000 Discrete
Krol K~Skoneczna A, 2015 growth (relative abundance in pooled culture) phleomycin D1 [5-15 ug/ml] het ~1,100 Discrete
Dobzinski N~Gerst JE, 2015 transport to vacuoles (GFP-Yif1) sirolimus [200 ug/L], temperature [26ÂșC] SC - Ura hap a 4,885 Discrete